| Anne E Davis, MS CCC SLP | |
|
425 Patterson Rd, Suite 503, Grand Junction, CO 81506 | |
| (970) 245-2400 | |
| (970) 242-9092 |
| Full Name | Anne E Davis |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 425 Patterson Rd, Grand Junction, Colorado |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134200587 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Anne E Davis, MS CCC SLP 425 Patterson Rd, Suite 503, Grand Junction, CO 81506 Ph: (970) 245-2400 | Anne E Davis, MS CCC SLP 425 Patterson Rd, Suite 503, Grand Junction, CO 81506 Ph: (970) 245-2400 |
News Archive
Nile Therapeutics, Inc., a company focused on the development of novel therapeutics for heart failure patients, announced today that it intends to offer units consisting of shares of its common stock and warrants to purchase shares of its common stock in a public offering. Maxim Group LLC is acting as the sole book-running manager for this offering, with Ladenburg Thalmann & Co. Ltd. as co-manager.
Hemoglobin A1c is the standard measurement for assessing glycemic control over time in people with diabetes. Blood levels of A1c are typically measured every few months in a laboratory, but now researchers have developed a data-based model that accurately estimates A1c using self-monitored blood glucose (SMBG) readings, as described in Diabetes Technology & Therapeutics (DTT), a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.
A new prospective study of six-month-old infants at high genetic risk for autism identified weak head and neck control as a red flag for autism spectrum disorder (ASD) and language and/or social developmental delays.
PuraMed BioScience, announced today that a clinical study of LipiGesic M has been completed. The study design was a double blind, placebo controlled, multi-site study measuring the effectiveness of LipiGesic™ M for the treatment of acute migraine attacks. The next steps include completion of the manuscript, submission for publication in a peer-reviewed medical journal and actual publication. In an effort to maximize the potential for publication, an embargo has been placed on the disclosure of any of the results of this study.
› Verified 8 days ago
Lindsay Drayer, M.S., CCC-SLP Speech-Language Pathologist Medicare: Accepting Medicare Assignments Practice Location: 2121 North Ave, Grand Junction, CO 81501 Phone: 970-244-1335 | |
Hannah Elizabeth Vranicar, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2115 Grand Ave, Grand Junction, CO 81501 Phone: 970-254-4872 | |
Ginger Williams, M.S, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2635 N 7th St, Grand Junction, CO 81501 Phone: 970-298-2043 | |
Madison Backes, Speech-Language Pathologist Medicare: Accepting Medicare Assignments Practice Location: 2635 N 7th St, Grand Junction, CO 81501 Phone: 970-298-2273 | |
Leisha Adams, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 618 Rood Ave, Grand Junction, CO 81501 Phone: 970-665-4744 | |
Jennifer Lee Mcclaskey, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 625 27 1/2 Rd, Grand Junction, CO 81506 Phone: 970-244-0719 | |
Alicia Mcartor, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2115 Grand Ave, Grand Junction, CO 81501 Phone: 970-254-4872 |